Global Targeted Protein Degradation Market By Technology (Proteolysis-Targeting Chimeras, Molecular Glues, Hydrophobic Tagging, Autophagy-Targeting Chimeras and Others), By Application (Oncology, Immunological Disorders, Neurodegenerative Diseases, Infectious Diseases and Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) and Academic and Research Institutes), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035
- Published date: April 2026
- Report ID: 184804
- Number of Pages: 288
- Format:
-
keyboard_arrow_up
-
-
- Arvinas Operations, Inc.
- C4 Therapeutics, Inc.
- Kymera Therapeutics, Inc.
- Nurix Therapeutics, Inc.
- Vividion Therapeutics, Inc. (Bayer)
- Plexium, Inc.
- Amphista Therapeutics Ltd.
- Neomorph, Inc.
- Captor Therapeutics S.A.
- Oncopia Therapeutics (Roivant Sciences)
- AbbVie Inc.
- Bristol-Myers Squibb Company
Our Clients
- 184804
- April 2026
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
